1. Home
  2. MEIP vs CCTG Comparison

MEIP vs CCTG Comparison

Compare MEIP & CCTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • CCTG
  • Stock Information
  • Founded
  • MEIP 2000
  • CCTG 1993
  • Country
  • MEIP United States
  • CCTG Hong Kong
  • Employees
  • MEIP N/A
  • CCTG N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • CCTG
  • Sector
  • MEIP Health Care
  • CCTG
  • Exchange
  • MEIP Nasdaq
  • CCTG Nasdaq
  • Market Cap
  • MEIP 13.3M
  • CCTG 14.9M
  • IPO Year
  • MEIP 2003
  • CCTG 2024
  • Fundamental
  • Price
  • MEIP $2.80
  • CCTG $1.06
  • Analyst Decision
  • MEIP Hold
  • CCTG
  • Analyst Count
  • MEIP 1
  • CCTG 0
  • Target Price
  • MEIP N/A
  • CCTG N/A
  • AVG Volume (30 Days)
  • MEIP 13.3K
  • CCTG 5.9K
  • Earning Date
  • MEIP 05-13-2025
  • CCTG 08-23-2025
  • Dividend Yield
  • MEIP N/A
  • CCTG N/A
  • EPS Growth
  • MEIP N/A
  • CCTG N/A
  • EPS
  • MEIP N/A
  • CCTG N/A
  • Revenue
  • MEIP N/A
  • CCTG $16,463,490.00
  • Revenue This Year
  • MEIP N/A
  • CCTG N/A
  • Revenue Next Year
  • MEIP N/A
  • CCTG N/A
  • P/E Ratio
  • MEIP N/A
  • CCTG N/A
  • Revenue Growth
  • MEIP 33.76
  • CCTG 3.27
  • 52 Week Low
  • MEIP $1.46
  • CCTG $0.99
  • 52 Week High
  • MEIP $4.10
  • CCTG $3.17
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 78.43
  • CCTG 39.49
  • Support Level
  • MEIP $2.21
  • CCTG $1.05
  • Resistance Level
  • MEIP $2.95
  • CCTG $1.12
  • Average True Range (ATR)
  • MEIP 0.15
  • CCTG 0.04
  • MACD
  • MEIP 0.05
  • CCTG 0.01
  • Stochastic Oscillator
  • MEIP 81.48
  • CCTG 46.67

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About CCTG CCSC Technology International Holdings Limited

CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas and Asia.

Share on Social Networks: